The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Increase In Market Value Is Predicted For The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market During The 2026–2030 Period?
The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market size has seen strong growth in recent years. It is forecast to increase from $6.11 billion in 2025 to $6.55 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.1%. The expansion observed historically stems from an increasing prevalence of chronic pancreatitis, growing awareness about digestive disorders, limited access to specialized diagnostics, the adoption of nutritional supplements, and the rise in home healthcare services.
The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market is projected to experience robust expansion over the coming years. This market is anticipated to reach a valuation of **$8.97 billion by 2030**, exhibiting a compound annual growth rate (CAGR) of **8.2%**. Several factors are set to drive this growth during the forecast period, including progress in personalized enzyme therapies, the incorporation of AI into diagnostics, an increasing need for non-invasive imaging techniques, the proliferation of telehealth services, and an intensified emphasis on nutritional management centered around the patient. Key developments expected within this timeframe encompass sophisticated pancreatic enzyme replacement therapies, diagnostic solutions available at the point of care, customized nutritional management programs, non-invasive imaging methods specifically for EPI, and the broader adoption of telehealth in EPI care.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp
What Major Growth Factors Are Impacting The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
The increasing number of people diagnosed with diabetes is anticipated to propel the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in the future. Diabetes is a chronic metabolic condition marked by persistently elevated blood sugar levels (hyperglycemia), stemming from the body’s inability to produce adequate insulin or to effectively utilize the insulin it does produce. Exocrine pancreatic insufficiency (EPI) therapy, including pancreatic enzyme replacement therapy (PERT), can aid in enhancing nutrient absorption and improving glycemic control for individuals with diabetes and EPI. For instance, as reported by The National Health Service (NHS England) in June 2024, the count of individuals identified with pre-diabetes in England reached 3,615,330 in 2023, signifying an 18% rise from 3,065,825 in 2022. Additionally, among those younger than 40, cases increased by nearly 25%, growing from 173,166 in 2022 to 216,440 in 2023. Consequently, the rising prevalence of diabetes is a significant factor driving the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. The rising occurrence of gastrointestinal diseases is projected to stimulate the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market going forward. Gastrointestinal diseases refer to a variety of medical conditions that impact the gastrointestinal tract, which comprises the organs responsible for the digestive process. Exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics play a vital role in the management of gastrointestinal diseases by addressing underlying enzyme deficiencies and facilitating proper nutrient digestion. For example, in June 2023, Crohn’s and Colitis Canada, a non-profit organization located in Canada, estimated that over 322,600 Canadians were living with inflammatory bowel diseases (IBD) in 2023, representing approximately 0.82% of the population. As the prevalence of IBD continues, it is estimated that around 470,000 Canadians will be affected by IBD by 2035, which would constitute approximately 1.1% of the population, or 1 in every 91 people in the country. Therefore, the increasing incidence of gastrointestinal diseases is expected to propel the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.
What Segment Types Are Included In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Analysis?
The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market covered in this report is segmented –
1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach
2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning
3) By Drug Type: Generic, Branded
4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels
5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users
Subsegments:
1) By Nutritional Management: Dietary Modifications, Nutritional Supplements
2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations
3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs
Which Trends Are Guiding The Development Of The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
Key companies operating within the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are adopting a strategic partnership model to enhance technology integration and expand their market reach. A strategic partnership generally describes a collaborative relationship between two or more entities that combine their resources, specialized knowledge, and efforts to achieve shared objectives. For example, in February 2023, Codexis, Inc., a US-based protein engineering company, and Nestlé Health Science, a Switzerland-based science of nutrition, disclosed interim results from their Phase 1 clinical trial of CDX-7108, an investigational therapy developed to treat exocrine pancreatic insufficiency (EPI). The outcomes from this Phase 1 trial create a pathway for future studies, which could considerably improve treatment options for individuals suffering from EPI.
Who Are The Prominent Players Across The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Abbott Laboratories, Metagenics LLC, Chiesi Farmaceutici S.p.A., Nordmark Arzneimittel GmbH & Co. KG, Digestive Care Inc., Bioserv Diagnostics Gmbh, Aptalis Pharma Inc., EagleBiosciences Inc., ScheBo Biotech AG, Solvay S.A., Codexis Inc., ChiRhoClin Inc., Alcresta Therapeutics Inc., Cilian AG, First Wave BioPharma Inc., Laboratory Corporation of America Holdings, Organon, Vivus Inc., Anthera Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd
Access The Complete Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report:
Which Region Is The Dominant Market In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2025. The regions covered in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp
Browse Through More Reports Similar to the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market 2026, By The Business Research Company
Exocrine Pancreatic Insufficiency Epi Therapeutics And Diagnostics Market Report 2026
Exocrine Pancreatic Insufficiency Market Report 2026
Acute Pancreatitis Market Report 2026
https://www.thebusinessresearchcompany.com/report/acute-pancreatitis-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model